Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model

Medical Oncology

Volumn 21, Issue 4, 2004, Pages 339-348

  Tsui, Paulus ^a   Rubenstein, Marvin ^a,b   Guinan, Patrick ^c  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense oligonucleotides; Carboplatin; Cisplatin; Cytoxan; Mitoxantrone; Oxaliplatin; Prostate cancer; Taxol; Therapy

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; GROWTH INHIBITION; HORMONAL THERAPY; HUMAN; HUMAN CELL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG INTERACTIONS; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 11244317097     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:4:339     Document Type: Article

References (19)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1991; 1: 293-297.
2. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Urol 1980; 17: 159-163.
3. Jemal A, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
4. Crawford ED, et al. A controlled trial of leuprolide with or without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-423.
5. Geiger T, Müller M, Monia B, Fabbro D. Antitumor activity of a C-raf antisense oligonucleotide in combinaton with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res 1997; 3: 1179-1185.
6. Mewani R, et al. Enhanced antitumor activity of liposome-entrapped antisense raf oligonucleotides (LErafAON) in combination with chemotherapeutic agents. Proc Am Assoc Cancer Res 2002; 43: 577a.
7. Miyake H, Monia B, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000; 86: 855-862.
8. Gleave M, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999; 5: 2891-2898.
9. Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligonucleotides and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001; 91: 846-850.
10. Rubenstein M, Slobodskoy L, Mirochnick Y, Guinan P. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and Taxol. Med Oncol 2003; 20: 29-35.
11. Chi KN, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
12. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 1996; 62: 194-200.
13. Rubenstein M, Mirochnik Y, Ray V, Guinan P. Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors. Med Oncol 1997; 14: 131-136.
14. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides. Meth Find Exp Clin Pharmacol 1998; 20: 825-831.
15. Rubenstein M, Glick R, Lichtor T, Mirochnik Y, Chou P, Guinan P. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-α and the epidermal growth factor receptor. Med Oncol 2001; 18: 121-130.
16. Rubenstein M, Chou P, Mirochnik Y, Guinan P. Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation. Med Oncol 1997; 14: 23-29.
17. Rubenstein M, Guinan P. A review of various antisense oligonucleotide therapeutic approaches for prostate cancer. The Prostate Journal 2000; 2: 179-188.
18. Zellweger T, et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Phamacol Exp Therapeutics 2001; 298: 934-940.
19. Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-α of EGFR in the treatment of prostate cancer cell lines. Meth Find Exp Clin Pharmacol 2002; 24: 649-652.